A safe and effective treatment for persistent pain first conceived of by
Dr John Lyftogt.
Every treatment aims to inhibit the pain. After the first treatment pain relief may last for a period of four hours to four days. Repeated treatments (6-8 sessions) usually done weekly, result in gradual reduction of the overall pain, with the aim of complete resolution - a zero pain score - and allow return of full function. Success rates vary between 80-100% depending on the condition. For most conditions recurrence is unlikely unless re-injury occurs.
The treatment is extremely safe; D5W is used as an IV solution in hospitals worldwide. Being mostly a subcutaneous treatment, and using only a half-inch needle, harm is minimised. There may be some bruising. No allergic reactions have yet been observed. Infection is extremely rare, calculated at about 1 in 300,000 injections. The only adverse reactions reported are temporary histamine induced welts at injection sites and extremely rare corn allergies. There are no reported issues of dependency.
Dr. Lyftogt says: "Pain is an enormous unmet need. Current treatment guidelines with antidepressants, antiepileptic and analgesics targeting Central Nervous System sensitisation benefit less than 25% of patients (Canadian pain society 2013). Opioids as a last resort are now creating an iatrogenic epidemic of opioid dependency worldwide".
From a knowledge base of traditional Prolotherapy (which uses glucose injections to treat painful conditions) he developed a new treatment which he initially named Neural Prolotherapy (NPT) but is now known as Lyftogt Perineural Injection Treatment (Lyftogt P.I.T®). The results of this treatment were so positive that soon his General Practice became flooded with patients with pain and injuries, both sporting and occupational.Dr John Lyftogt and his wife Maria organised the first Lyftogt Perineural Injection Treatment teaching event in Christchurch in November 2009. Workshop attendances now number over 3500; health professionals from more than 30 countries who have attended Dr Lyftogt's educational events in New Zealand, Argentina, Australia, Canada, Egypt, Germany, Italy, Jordan, the Netherlands, the Philippines, South Korea, Spain, Taiwan, Turkey, Malaysia, Mexico and the USA.
Randomised Control Trials (RCT’s) on treatments using 5% Dextrose have been published on caudal epidurals for chronic low back pain; achilles tendonitis and carpal tunnel syndrome, including a 3-year prospective case series on 201 Achilles Tendons with a 92% success rate at 12 month follow-up. Similar results have been published for chronic knee, compartment syndrome, elbow and shoulder pain. Research is now being undertaken in many countries.
D5W is used as an IV solution in hospitals worldwide. Being mostly a subcutaneous treatment and using only a 1/2 inch needle, harm is minimised
Every treatment aims to extinguish the pain. After the first treatment pain relief may last for a period of 4 hours to 4 days. Repeated treatments (6-8 sessions) usually done weekly, result in a gradual reduction of the overall pain, with the aim of complete resolution
The treatment consists of a series of small injections immediately under the skin targeting painful areas where the nerves are sensitive, with non-pharmacological ingredients. The substance Dr Lyftogt uses is a buffered D5W (dextrose 5% in sterile water) with a neutral pH of 7.4